Protocol for initiation of miglustat treatment in NP-C. Reproduced

SEC Filing Orphazyme A/S

Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect, Orphanet Journal of Rare Diseases

Protocol for initiation of miglustat treatment in NP-C. Reproduced with

MRx Pipeline October by Magellan Rx Management - Issuu

Phenotypic expression of swallowing function in Niemann–Pick disease type C1, Orphanet Journal of Rare Diseases

Miglustat - wikidoc

Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin. - Abstract - Europe PMC

Elucidating the mechanism of cyclodextrins in the treatment of Niemann-Pick Disease Type C using crosslinked 2-hydroxypropyl-β-cyclodextrin

PDF) Goal-oriented therapy with miglustat in Gaucher disease

Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

Distinct Niemann-Pick Disease Type C Clinical, Cytological, and Biochemical Phenotype in an Adult Patient With 1 Mutated, Overexpressed NPC1 Allele - Julia Jecel, Klaus Harzer, Eduard Paschke, Stefanie Beck-Wödl, Peter Bauer, Milos

Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease. - Abstract - Europe PMC